import 'package:flutter/material.dart';

class Category {
  final String id;
  final String name;

  final AssetImage image;
  Category(
    this.id,
    this.name,
    this.image,
  );
}

class CategoryProvider with ChangeNotifier {
  List<Category> _categories = [
    Category('a', 'Antipyretic', AssetImage('assets/images/fever.png')),
    Category('b', 'Common Cold', AssetImage('assets/images/commoncold.png')),
    Category('c', 'Antibiotics', AssetImage('assets/images/antibiotics.png')),
    Category('d', 'GIT', AssetImage('assets/images/git.png')),
    Category('e', 'Respiratory', AssetImage('assets/images/respiratory.png')),
  ];

  List<Category> get categories {
    return [..._categories];
  }
}

class Drug {
  final String id;
  final String cat;
  final String genericName;
  final String tradeName;
  final double conc;
  final List<String> contra;
  final List<String> prec;
  final double minD;
  final double maxD;
  final String freq;
  final String doseNote;
  Drug(
      {this.id,
      this.genericName,
      this.tradeName,
      this.conc,
      this.cat,
      this.contra,
      this.maxD,
      this.minD,
      this.freq,
      this.doseNote,
      this.prec});
}

class AntipyreticProvider with ChangeNotifier {
  List<Drug> _drugs = [
    Drug(
        id: 'a',
        tradeName: 'Cetal 250mg/5ml 60ml susp',
        genericName: 'Paracetamol',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 250,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 'b',
        tradeName: 'BRUFEN 100MG/5ML SUSP. 150ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'c',
        tradeName: 'ALPHAFEN 100MG/5ML SUSP. 120 ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'd',
        tradeName: 'ALPHAFEN 100MG/5ML SUSP. 60 ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'e',
        tradeName: 'CETAFEN-N 120ML SUSP.',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'f',
        tradeName: 'CONTAFEVER N 200MG/5ML SUSP. 120ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 200MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 200,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'g',
        tradeName: 'IBUCALMIN 100MG/5ML SYRUP 120 ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'h',
        tradeName: 'IBUFEN 2% SUSP. 120ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'i',
        tradeName: 'IBUFEN 2% SUSP. 60ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'j',
        tradeName: 'IBUFLAM N 120ML SUSP.',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'k',
        tradeName: 'IBUPROFEN 100MG/5ML SUSP. 120 ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'l',
        tradeName: 'JUSPOLED 100MG/5ML SUSP. 120 ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'm',
        tradeName: 'MARCOFEN 100MG/5ML SUSP. 120ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'n',
        tradeName: 'MEGAFEN-N 100MG/5ML SUSP. 120 ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'o',
        tradeName: 'NOVA-PROFEN  100MG/5ML ORAL SUSP. 100ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'p',
        tradeName: 'PROFINAL PAEDIATRIC 20MG/ML SUSP. 110ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'q',
        tradeName: 'PROFINAL PAEDIATRIC 20MG/ML SUSP. 60ML',
        cat: 'Antipyretic',
        genericName: 'Ibuprofen 100MG/5ML SUSP',
        prec: [
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          'Heart Failure (HF) risk',
          'NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics',
          'NSAIDS should be avoided or withdrawn whenever possible',
        ],
        minD: 5,
        maxD: 10,
        conc: 5 / 100,
        freq: 'PO q6-8hr; not to exceed 400 mg/dose or 40 mg/kg/day',
        doseNote: '<6 monthsSafety and efficacy not established',
        contra: [
          'Hypersensitivity to drug, other NSAIDs, aspirin, or excipients',
          'Perioperative pain in setting of coronary artery bypass graft (CABG) surgery'
        ]),
    Drug(
        id: 'r',
        tradeName: 'ABIMOL 150MG/5ML 125ML SYRUP',
        genericName: 'Paracetamol 150MG/5ML',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 150,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 's',
        tradeName: 'CETAMOL 120MG/5ML PEDIATRIC SYRUP 120 ML',
        genericName: 'Paracetamol 120MG/5ML',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 120,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 't',
        tradeName: 'FEVANO 200MG/5ML SYRUP 125ML',
        genericName: 'Paracetamol 200MG/5ML',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 200,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 'u',
        tradeName: 'PARACETAMOL-AMRIYA 120MG/5ML 120ML SUSP.',
        genericName: 'Paracetamol 120MG/5ML',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 120,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 'v',
        tradeName: 'PARAMOL 120MG/5ML SYRUP 125ML',
        genericName: 'Paracetamol 120MG/5ML',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 120,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 'x',
        tradeName: 'TEMPORAL 250MG/5ML SUSP. 60 ML',
        genericName: 'Paracetamol 250MG/5ML',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 250,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 'y',
        tradeName: 'TEMPRA 160 MG/5ML SYP. 90 ML',
        genericName: 'Paracetamol 160MG/5ML',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 160,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 'z',
        tradeName: 'THERA-LO 3.2G/100ML ORAL SUSP. 100 ML',
        genericName: 'Paracetamol 160MG/5ML',
        cat: 'Antipyretic',
        contra: ['Hypersensitivity', 'Severe active liver disease'],
        conc: 5 / 160,
        minD: 10,
        maxD: 15,
        freq: 'PO q6-8hr prn',
        doseNote: '',
        prec: [
          'Hypersensitivity and anaphylactic reactions reported; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur',
          ' Acetaminophen is available in many dosage forms and products, check label carefully to avoid overdose',
          ' Use caution in patients with hepatic impairment or active liver disease',
          ' Risk of hepatotoxicity is higher in patients taking chronic high dose or use of more than one acetaminophen-containing product',
          ' Use caution in patients with severe renal impairment; consider dosage adjustments, Consumption of 3 or more alcoholic drinks/day may increase risk of liver damage',
          ' Use with caution in patients with G6PD deficiency',
          ' Use caution in patients with chronic malnutrition',
          ' Risk for rare but serious skin reactions that can be fatal; these reactions include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP); symptoms may include skin redness, blisters and rash',
          ' Limit acetaminophen dose from all sources and routes to <4 g/day in adults',
        ]),
    Drug(
        id: 'aa',
        tradeName: 'CATAFLY 2MG/ML SUSP. 140ML',
        genericName: 'Diclofenac potassium 2MG/ML',
        cat: 'Antipyretic',
        contra: [
          "Absolute: Hypersensitivity to diclofenac, history of aspirin triad, treatment of perioperative pain associated with CABG; active gastrointestinal bleeding",
          "IV: Moderate-to severe renal insufficiency in the perioperative period and patients who are at risk for volume depletion",
        ],
        conc: 1 / 2,
        minD: 2,
        maxD: 3,
        freq: 'PO /day for up to 4 weeks',
        doseNote: '<3 years: Safety and efficacy not established',
        prec: [
          "Use caution in patients with bronchospasm, cardiac disease, CHF, hepatic porphyria, hypertension, fluid retention, severe renal impairment, smoking, systemic lupus erythematosus",
          "Platelet aggregation and adhesion may be decreased; may prolong bleeding time",
          "Use caution in blood dyscrasias or bone marrow depression; also with thrombocytopenia, agranulocytosis, and aplastic anemia",
          "Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals, those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers",
          "Therapy may increase risk of hyperkalemia, especially in renal disease, diabetics, the elderly, and concomitant use of agents that may induce hyperkalemia; monitor potassium closely",
          "May cause dizziness blurred vision and neurologic effects that may impair physical and mental abilities",
          "Risk of serious skin reactions, including Stevens Johnson syndrome and necrotizing enterocolitis",
          "Persistent urinary symptoms, including bladder pain and dysuria, hematuria or cystitis may occur after initiating therapy; discontinue therapy with symptom onset and evaluate cause",
          "Increase in transaminase levels reported within 2 months of therapy; may occur at any time; monitor transaminase levels periodically beginning 4-8 weeks after initiation of therapy",
          "May increase risk of aseptic meningitis (rare), especially in patients with systemic lupus erythrmatosus, and mixed connective tissue disorders",
          "Use caution if patient dehydrated before initiating therapy; rehydrate patient before initiating therapy and monitor renal function closely",
          "Injectable dosage form not recommended for long-term use",
          "Overuse of acute migraine drugs (eg, ergotamine, triptans, opioids, nonsteroidal anti-inflammatory drugs or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache); may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks; detoxification of patients, including withdrawal of overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary",
          "Different formulations not bioequivalent even if milligram strength the same; do not interchange products",
          "Withhold for at least 4-6 half-lives prior to surgical or dental procedures",
          "NSAIDS have the potential to trigger HF by prostaglandin inhibition that leads to sodium and water retention, increased systemic vascular resistance, and blunted response to diuretics",
          "NSAIDS should be avoided or withdrawn whenever possible",
        ]),
    Drug(
        id: 'ab',
        tradeName: '1  2  3 (ONE TWO THREE) SYRUP 120 ML',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'ac',
        tradeName: 'ACTIFED SYRUP 120ML',
        genericName: 'PSEUDOEPHEDRINE+TRIPROLIDINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 5ml/8 hrs',
        prec: [
          "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)",
          "Antihistamines may cause excitation in young children",
          "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever",
          "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur",
          "Do not exceed recommended dose",
        ]),
    Drug(
        id: 'ad',
        tradeName: 'ADVIPRO COUGH & COLD SYRUP 120ML',
        genericName:
            'CHLORPHENIRAMINE+DEXTROMETHORPHAN+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 5ml/8 hrs',
        prec: [
          "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)",
          "Antihistamines may cause excitation in young children",
          "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever",
          "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur",
          "Do not exceed recommended dose",
          "Dextromethorphan:Phenylketonuria: Contains aspartame",
          "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur",
          "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton",
        ]),
    Drug(
        id: 'ae',
        tradeName: 'ADVIPRO COUGH & COLD SYRUP 120ML',
        genericName:
            'CHLORPHENIRAMINE+DEXTROMETHORPHAN+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)",
          "Antihistamines may cause excitation in young children",
          "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever",
          "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur",
          "Do not exceed recommended dose",
          "Dextromethorphan:Phenylketonuria: Contains aspartame",
          "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur",
          "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton",
        ]),
    Drug(
        id: 'af',
        tradeName: 'COLD STOP SYRUP 120 ML',
        genericName:
            'CHLORPHENIRAMINE+DEXTROMETHORPHAN+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)",
          "Antihistamines may cause excitation in young children",
          "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever",
          "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur",
          "Do not exceed recommended dose",
          "Dextromethorphan:Phenylketonuria: Contains aspartame",
          "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur",
          "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton",
        ]),
    Drug(
        id: 'ag',
        tradeName: 'CONGESTAL SYRUP 120ML',
        genericName:
            'CHLORPHENIRAMINE+DEXTROMETHORPHAN+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)",
          "Antihistamines may cause excitation in young children",
          "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever",
          "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur",
          "Do not exceed recommended dose",
          "Dextromethorphan:Phenylketonuria: Contains aspartame",
          "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur",
          "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton",
        ]),
    Drug(
        id: 'ah',
        tradeName: 'BABYRHINO SYRUP 100ML',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'ai',
        tradeName: 'FEVER N FLU 120ML SYRUP',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'aj',
        tradeName: 'FLUMOL SYRUP 120ML',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'ak',
        tradeName: 'NOFLU SYRUP 100ML',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'al',
        tradeName: 'NEO-MICHAELON SUSP. 120ML',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'am',
        tradeName: 'RHINOCALM SYRUP 120ML',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'an',
        tradeName: 'RHINOMOL-S SYRUP 120ML',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'ao',
        tradeName: 'VEGASKINE SYRUP 120ML',
        genericName:
            'CHLORPHENIRAMINE+PARACETAMOL(ACETAMINOPHEN)+PHENYLPROPANOLAMINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
        ]),
    Drug(
        id: 'ap',
        tradeName: 'CEVANDRA SYRUP 120 ML',
        genericName:
            'DEXTROMETHORPHAN+DOXYLAMINE SUCCINATE+PARACETAMOL(ACETAMINOPHEN)',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Not to exceed 2 weeks of use",
          "Caution in hepatic failure",
          "Dextromethorphan:Phenylketonuria: Contains aspartame",
          "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur",
          "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton",
        ]),
    Drug(
        id: 'aq',
        tradeName: 'PENTAFLU SYRUP 100 ML',
        genericName:
            'DEXTROMETHORPHAN+DOXYLAMINE SUCCINATE+PARACETAMOL(ACETAMINOPHEN)',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Within 14 days of MAO inhibitor therapy",
          "Acute asthma, sleep apnea",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Not to exceed 2 weeks of use",
          "Caution in hepatic failure",
          "Dextromethorphan:Phenylketonuria: Contains aspartame",
          "Dextromethorphan: Hallucinations, confusion, agitation, hyper-reflexia, shivering, myoclonus, and tachycardia may occur",
          "Dextromethorphan: Use caution in patients who are sedated, debilitated or confined to supine posiiton",
        ]),
    Drug(
        id: 'ar',
        tradeName: 'DOLO-D ORAL SUSP. 115 ML',
        genericName: 'IBUPROFEN+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
        ]),
    Drug(
        id: 'ar',
        tradeName: 'DOLO-D PLUS ORAL SUSP. 115 ML',
        genericName: 'CHLORPHENIRAMINE+IBUPROFEN+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)",
          "Antihistamines may cause excitation in young children",
          "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever",
          "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur",
          "Do not exceed recommended dose",
        ]),
    Drug(
        id: 'as',
        tradeName: 'DOLO-D PLUS ORAL SUSP. 115 ML',
        genericName: 'CHLORPHENIRAMINE+IBUPROFEN+PSEUDOEPHEDRINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 10ml/8 hrs',
        prec: [
          "Use caution in mild to moderate hypertension, cardiac disease, hyperthyroidism, hyperglycemia, BPH, DM, renal impairment, seizure disorder, thyroid dysfunction, glaucoma, lactation",
          "When used for self-medication, see health-care provider if symptoms do not improve within 7 days or are accompanied by fever",
          "Some products may contain sodium",
          "Some dosage forms may contain sodium benzoate/benzoic acid; large amounts have been associated with a potentially fatal toxicity (gasping syndrome) in neonates",
          "Many combo formulations are switching to phenylephrine due to restrictions arising from easy conversion to methamphetamine (the Combat Methamphetamine Epidemic Act of 2005 bans OTC sales of cold medicines that contain ingredients, such as pseudoephedrine, commonly used to make methamphetamine)",
          'Use caution in asthma (bronchial), cardiac disease, congestive heart failure (CHF), hepatic or renal impairment, hypertension. bleeding disorder, duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus (SLE), ulcerative colitis, upper GI disease, late pregnancy (may cause premature closure of ductus arteriosus)',
          'Long-term administration of NSAIDs may result in renal papillary necrosis and other renal injury; patients at greatest risk include elderly individuals; those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion; and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers',
          'Junior Advil (100 mg): Doses higher than recommended may cause stomach bleeding',
          'May cause serious adverse reactions, including exfoliative dermatitis, toxic epidermal necrolysis, Steven Johnson syndrome reported',
          "Children's and Junior Advil (50 mg, 100 mg): May cause severe and persistent sore throat",
          'Fever, rash, abdominal pain, nausea, liver dysfunction, and meningitis have occurred in patients with collagen-vascular disease, especially SLE',
          'Blurred vision, scotomate, and changes in color vision reported; discontinue therapy if symptoms occur',
          'Platelet aggregation and adhesion may be decreased; monitor patients with coagulation disorders receiving the therapy',
          'Risk of hyperkalemia may increase in patients with diabetes, the elderly, renal disease, or with concomitant use of agents that can induce hyperkalemia including ACE inhibitors; monitor potassium closely',
          'May cause drowsiness and dizziness; may impair physical or mental abilities to operate heavy machinery or driving',
          'NSAIDS, except aspirin, increase risk of heart attack, heart failure, and stroke; which can be fatal; the risk is higher if patients use more than it was directed or for longer than needed',
          'Use caution in patients with high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, thyroid disease, diabetes, glaucoma, have trouble urinating due to an enlarged prostate gland, or had a stroke',
          'Patients should inform healthcare professional if they have symptoms of heart problems or stroke, chest pain, trouble breathing weakness in one part or side of body, slurred speech, leg swelling',
          'Not for use right before or after heart surgery',
          "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)",
          "Antihistamines may cause excitation in young children",
          "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever",
          "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur",
          "Do not exceed recommended dose",
        ]),
    Drug(
        id: 'at',
        tradeName: 'HISTARHINE SYRUP 100ML',
        genericName: 'PSEUDOEPHEDRINE+TRIPROLIDINE',
        cat: 'Common Cold',
        contra: [
          "Hypersensitivity",
          "Severe hypertension, severe CAD",
          "Within 14 days of MAO inhibitor therapy",
        ],
        conc: 0,
        minD: 0,
        maxD: 0,
        freq: 'PO /day for up to 4 weeks',
        doseNote:
            '<6 years: Safety and efficacy not established, >=6 years 5ml/8 hrs',
        prec: [
          "May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)",
          "Antihistamines may cause excitation in young children",
          "Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever",
          "Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur",
          "Do not exceed recommended dose",
        ]),
    Drug(
        id: 'au',
        tradeName: 'AMOXICID 125MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN 125MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 125,
        minD: 15,
        maxD: 20,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'av',
        tradeName: 'BIOMOX 125MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 125MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 125,
        minD: 15,
        maxD: 20,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aw',
        tradeName: 'E-MOX 125MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN 125MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 125,
        minD: 15,
        maxD: 20,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'ax',
        tradeName: 'E-MOX 125MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 125MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 125,
        minD: 15,
        maxD: 20,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'ay',
        tradeName: 'HICONCIL 125MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN 125MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 125,
        minD: 15,
        maxD: 20,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'az',
        tradeName: 'HICONCIL 125MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 125MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 125,
        minD: 15,
        maxD: 20,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdz',
        tradeName: 'MOXIPEN 125MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 125MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdsdz',
        tradeName: 'AMOXICID 250MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdvdsdz',
        tradeName: 'AMOXIL FORT 250MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdasdvdsdz',
        tradeName: 'AMOXIL FORT 250MG/5ML SUSP. 100ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdassdfdvdsdz',
        tradeName: 'AMOXYCILLIN 250 MG/5 ML SUSP. 100 ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aas2dassdfdvdsdz',
        tradeName: 'AMOXYCILLIN 250 MG/5 ML SUSP. 80 ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdassdfsdsdfdvdsdz',
        tradeName: 'BIOMOX 250MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdassdfsd4sdfdvdsdz',
        tradeName: 'E-MOX 250MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdassdfsd4sdfd3vdsdz',
        tradeName: 'E-MOX 250MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdassdfsd4sdfdw3vdsdz',
        tradeName: 'HICONCIL 250MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdas1sdfsd4sdfdw3vdsdz',
        tradeName: 'HICONCIL 250MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdas1sdf3sd4sdfdw3vdsdz',
        tradeName: 'MOXIPEN 250MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 250MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdas1sdf3sd4ssdfdw3vdsdz',
        tradeName: 'IBIAMOX 200MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 200MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdas1sdf3sd4ssdfdw3vds4dz',
        tradeName: 'DELPEDOX 400MG/5ML PD. FOR ORAL SUSP. 100ML',
        genericName: 'AMOXICILLIN 400MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 400,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdas1sdf3sdh4ssdfdw3vds4dz',
        tradeName: 'IBIAMOX 400MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN 400MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 400,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdas1sdf3sdhb4ssdfdw3vds4dz',
        tradeName: 'ORGANOMOX 400MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'AMOXICILLIN 400MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity to penicillins, cephalosporins, imipenem"
        ],
        conc: 5 / 400,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Anaphylaxis has been reported rarely but is more likely to occur following parenteral therapy with penicillins",
          "Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents; severity may range from mild diarrhea to fatal colitis; CDAD may occur over 2 months after discontinuation of therapy; if CDAD is suspected or confirmed, discontinue immediately and begin appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile, and surgical evaluation",
          "Do not administer in patients with infectious mononucleosis because of risk of development of erythematous skin rash",
          "Do not administer to patients in the absence of a proven or suspected bacterial infection because of risk of development of drug-resistant bacteria",
          "Superinfections with bacterial or fungal pathogens may occur during therapy; if suspected, discontinue immediately and begin appropriate treatment",
          "Chewable tablets contain aspartame, which contains phenylalanine",
          "Use caution in patients with allergy to cephalosporins, carbapenems",
          "Endocarditis prophylaxis: use for only high-risk patients, as per recent AHA guidelines",
          "High doses may cause false urine glucose test by some methods",
        ]),
    Drug(
        id: 'aasdas1sdf3sdh1b4ssdfdw3vdhdhfs4dz',
        tradeName: 'AUGMENTIN 156 MG/5 ML SUSP. 80 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 156MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 156,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf43sdh1b4ssdfdw3asfasvds4dz',
        tradeName: 'AUGMENTIN 312 MG/5 ML SUSP. 80 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf43sdh1qwrwqrb4ssdfdw3vds4dz',
        tradeName: 'AUGMENTIN 228 MG/5 ML SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sfsffdf43sdh1b4ssdfdw3vds4dz',
        tradeName: 'AUGMENTIN 457 MG/5 ML SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf43sdh1b4ssdfdwd3vds4dz',
        tradeName: 'AMOCLAWIN 228.5MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddf43sdh1b4ssdfdwd3vds4dz',
        tradeName: 'AMOXILANIC 228.5MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1fdfsdf43sdh1b4ssdfdwd3vds4dz',
        tradeName: 'AMOCLAWIN 457MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddf43sdh1b4sssssdfdwd3vds4dz',
        tradeName: 'AMOXILANIC 457MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457G/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddf43sdh1b4ssdfdwdada3vds4dz',
        tradeName: 'AUGMACILLIN 228.5 MG/5ML SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1fdfsdf43sdh1b4ssdfdwd3vvnsdds4dz',
        tradeName: 'AUGMACILLIN 457MG/5ML SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddddf43sdh1b4ssdfdwdada3vds4dz',
        tradeName: 'AUGRAM 228.5 MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1fdfsdf43sdhsdf1b4ssdfdwd3vsdds4dz',
        tradeName: 'AUGRAM 457 MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddddf43ssssfdh1b4ssdfdwdada3vds4dz',
        tradeName: 'CLAVIMOX 228.5MG/5ML PD. FOR ORAL SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1fsfsddfsdf43sdhsdf1b4ssdfdwd3vsdds4dz',
        tradeName: 'CLAVIMOX 457MG/5ML PD. FOR ORAL 75 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf3sdcvncvh1b4ssdfdw3vds4dz',
        tradeName: 'CLAVIMOX 312.5MG/5ML PD. FOR ORAL 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf3saadsdcvncvh1b4ssdfdw3vds4dz',
        tradeName: 'CLAVOSIGMA 250MG/62.5MG SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sw3vdhs4dz',
        tradeName: 'CLAVUCIN 156 MG/5 ML 60ML SUSP. (N/A)',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 156MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 156,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdddfdfas1sw3vds4dz',
        tradeName: 'CURAM 156.25/5ML PD. FOR ORAL SUSP. 75ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 156MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 156,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdddfsdfdfas1sw3vds4dz',
        tradeName: 'CURAM 312.5 MG/5ML PD. FOR ORAL SUSP. 75ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdddfsvcnvdfdfas1sw3vds4dz',
        tradeName: 'CURAM 228.5MG/5ML PD. FOR ORAL SUSP. 75ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddcxvdfsdfddgddfas1sw3vds4dz',
        tradeName: 'CURAM 457MG/5ML PD. FOR ORAL SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdddfsvcnvdsdfsfdfas1sw3vds4dz',
        tradeName: 'DELTACLAV 228.5MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddcxvdfsdfsdfsddgdadsdfas1sw3vds4dz',
        tradeName: 'DELTACLAV 457MG/5ML PD. FOR ORAL 80ML SUSP.',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdddfsvcZzcnvdsdfsfdfas1sw3vds4dz',
        tradeName: 'DEXICLAVE 312.5MG/5ML SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddcxvdfsdfsdsxcvxcdfsdfsddgdadsdfas1sw3vds4dz',
        tradeName: 'DEXICLAVE 457MG/5ML SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf3sdh1sdsb4ssdfdw3vds4dz',
        tradeName: 'E-MOXCLAV 156MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 156MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 156,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf43sdh1bxcv4ssdfdw3vds4dz',
        tradeName: 'E-MOXCLAV 312 MG/5ML DRY MIX FOR ORAL SUSP. 60ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1ssdfdf43sdh1b4ssdfdws3vds4dz',
        tradeName: 'E-MOXCLAV 228.5MG DRY SUSP. 75 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdasfs1sdf43sdh1b4ssdfdw3vds4dz',
        tradeName: 'E-MOXCLAV 457MG SUSP. 70 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf3sdhfgh1sdsb4ssdfdw3vds4dz',
        tradeName: 'GARDINOVA 156MG/5ML 70ML SUSP.',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 156MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 156,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdf4sdf3sdh1bxcv4ssdfdw3vds4dz',
        tradeName: 'GARDINOVA 312MG/5ML 70ML SUSP.',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdasfs1sdfsdf43sdh1b4ssdfdw3vds4dz',
        tradeName: 'GARDINOVA 457MG/5ML 70ML SUSP.',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdfdw3vds4dz',
        tradeName: 'HIBIOTIC 312MG/5 ML 60ML SUSP.',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdas1sdfxvx4sdf3sdh1bxcv4ssdfdw3vds4dz',
        tradeName: 'HIBIOTIC N 228MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdasfs1sdfsdf43sdhsfs1b4ssdfdw3vds4dz',
        tradeName: 'HIBIOTIC N 457MG/5ML SUSP. 60ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddz',
        tradeName: 'KLAVOX 228MG/5ML SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdasfs1sdfsdf43sdhsfs1b4ssdfsdfdw3vds4dz',
        tradeName: 'KLAVOX 457MG/5ML SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdasfs1sdfsdf43sdhsfs',
        tradeName: 'LARYNCLAVE 400/57 PD. FOR ORAL SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdfdvnvbw3vds4dz',
        tradeName: 'LARYNCLAVE 125/31 PD. FOR ORAL SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 156MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 156,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdfdxcvdfgfdxcw3vds4dz',
        tradeName: 'LARYNCLAVE 250/62 PD. FOR ORAL SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdfdvnvbwghjgh3vds4dz',
        tradeName: 'MAGNABIOTIC 156.25MG/5ML SUSP. 80 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 156MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 156,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdfdxcvdfsdfsgfdxcw3vds4dz',
        tradeName: 'MAGNABIOTIC 312.5MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 312MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 312,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdfdvnvbwsdfsghjgh3vds4dz',
        tradeName: 'MEGACLAVOX 156MG/5ML PD. FOR SUSP. 60 ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 156MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 156,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasddsdfsdz',
        tradeName: 'MEGAMOX 228MG SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 228MG/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 228,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdassdfsdfdw3vds4dz',
        tradeName: 'MEGAMOX 457MG/5ML SUSP. 70ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdasdfsssdfsdfdw3vds4dz',
        tradeName: 'NEW-CLAV 457MG/5ML SUSP. 80ML',
        genericName: 'AMOXICILLIN/CLAVULANIC ACID 457/5ML',
        cat: 'Antibiotics',
        contra: [
          "Allergy to penicillins",
          "Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin/clavulanate",
          "Extended release: Hemodialysis patients and severe renal impairment (CrCl <30 mL/min)"
        ],
        conc: 5 / 457,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Allergy to cephalosporins, carbapenems",
          "Different tablets are not interchangeable, because ratios of amoxicillin to clavulanate are different",
          "Extended release tablets not for use in renal impairment (CrCl <30 mL/min)",
          "Incidence of diarrhea is higher than with amoxicillin alone",
          "Unknown safety and efficacy of extended-release tablets in patients <16 years old",
          "Risk of Clostridium difficile-associated diarrhea (CDAD); consider in patients who present with diarrhea after antibiotic use; CDAD has been known to occur over 2 months after antibiotic therapy; if suspected, discontinue drug immediately and administer appropriate fluid/electrolyte therapy, protein supplementation, and C difficile antibiotic treatment",
          "Risk of bacterial or fungal superinfections; if suspected, discontinue drug immediately and administer appropriate therapy",
          "High percentage of patients with mononucleosis reported to develop rash during therapy; ampicillin-class antibiotics not recommended in these patients",
          "Use caution in hepatic impairment; hypatic dysfunction (rare) is more common in elderly and/or males and prolonged therapy may increase risk; may occur after completing therapy",
        ]),
    Drug(
        id: 'aasdasxfbdfsssdfsdfdw3vds4dz',
        tradeName: 'AZALIDE 200MG/5ML SUSP. 15ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfbdfsssdfsdvbfdw3vds4dz',
        tradeName: 'AZATRIBACT 200MG/5ML SUSP. 22.5 ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfvsdvbfddfgdw3vds4dz',
        tradeName: 'AZI-ONCE 200MG/5ML SUSP. 22.5ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfvsdvbfdw3vdfds4dz',
        tradeName: 'AZI-ONCE 200MG/5ML SUSP. 30ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdazfdsxfvsdvbfdw3vdfds4dz',
        tradeName: 'AZIWOK 200MG/5ML SUSP. 15ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfvsdvdsfgdfgbfdw3vdfds4dz',
        tradeName: 'AZOMYCIN 200MG/5ML SUSP. 15ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfvsdvbdgdffdw3vdfds4dz',
        tradeName: 'AZROLID 200MG/5ML PD. FOR ORAL SUSP. 15ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfcvbcvvsdvbdgdffdw3vdfds4dz',
        tradeName: 'AZROLID 200MG/5ML PD. FOR ORAL SUSP. 22.5ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfzczxvsdvbdgdffdw3vdfds4dz',
        tradeName: 'AZROLID 200MG/5ML PD. FOR ORAL SUSP. 30ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfvzxczsdvbdgdffdw3vdfds4dz',
        tradeName: 'BADOZITHRO 200MG/5ML PD. FOR ORAL SUSP. 15 ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdas45645gdffdw3vdfds4dz',
        tradeName: 'EPIZITHRO 200MG/5ML 15ML SUSP.',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aas84dz',
        tradeName: 'EPIZITHRO 200MG/5ML 30ML SUSP.',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdas1dfds4dz',
        tradeName: 'GIGAZOCIN 200MG/5ML PD. ORAL SUSP. 25 ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfvz1w3vdfds4dz',
        tradeName: 'RAME-ZITHRO 200MG/5ML SUSP. 15 ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfvz1ghjghw3vdfds4dz',
        tradeName: 'UNIZITHRIN 100MG/5ML SUSP. 30ML',
        genericName: 'AZITHROMYCIN 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfssdfsdvz1w3vdfds4dz',
        tradeName: 'UNIZITHROCURE 200MG/5ML PD. FOR ORAL SUSP. 15ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdasxfvxcvxcz1w3vdfds4dz',
        tradeName: 'XEREXOMAIR 100MG/5ML PD. FOR ORAL SUSP. 30ML',
        genericName: 'AZITHROMYCIN 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdsadadasnm,nxfvz1w3vdfds4dz',
        tradeName: 'XITHRONE 200 MG/5ML SUSP. 15ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdsadadasxxvxfvz1w3vdfds4dz',
        tradeName: 'XITHRONE 200 MG/5ML SUSP. 25ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdsadadascvbcvxfvz1w3vdfds4dz',
        tradeName: 'ZISROCIN 100MG/5ML SUSP. 30ML',
        genericName: 'AZITHROMYCIN 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdsadadasxfvcvbcvbz1w3vdfds4dz',
        tradeName: 'ZITHRODOSE 100MG/5ML SUSP. 15ML',
        genericName: 'AZITHROMYCIN 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdsadazxczxdasxfvz1w3vdfds4dz',
        tradeName: 'ZITHRODOSE 100MG/5ML SUSP. 30ML',
        genericName: 'AZITHROMYCIN 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdsadaczxcdasxfvz1w3vdfds4dz',
        tradeName: 'ZITHRODOSE 100MG/5ML SUSP. 45ML',
        genericName: 'AZITHROMYCIN 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasgfhfghfgdz',
        tradeName: 'ZITHRODOSE 100MG/5ML SUSP. 60ML',
        genericName: 'AZITHROMYCIN 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasdsadaczxcdasxfvz1w3vdghfds4dz',
        tradeName: 'ZITHROKAN 100MG/5ML PD. FOR ORAL SUSP. 15 ML',
        genericName: 'AZITHROMYCIN 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasddfgvdfds4dz',
        tradeName: 'ZITHROKAN 200MG/5ML PD. FOR ORAL SUSP. 15 ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasddfgdfgdfvdfds4dz',
        tradeName: 'ZITHROMAX 200MG/5ML SUSP. 15ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasddfgasdasdvdfds4dz',
        tradeName: 'ZITHROMAX 200MG/5ML SUSP. 22.5ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasddzxczxcfgvdfds4dz',
        tradeName: 'ZITHROMAX 200MG/5ML SUSP. 30ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasddfzczxczxs4dz',
        tradeName: 'ZITHROPHATE 200MG/5ML SUSP. 15ML',
        genericName: 'AZITHROMYCIN 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to azithromycin, erythromycin, any macrolides or ketolides",
          "History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Use only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria in order to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin',
        prec: [
          "Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death; discontinue treatment immediately if signs and symptoms of hepatitis occur",
          "Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported; advise direct parents and caregivers if vomiting or irritability with feeding occurs",
          "Clostridium difficile associated diarrhea (CDAD) has been reported, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported",
          "Antibacterial agents used to treat nongonococcal urethritis may mask or delay the symptoms of incubating syphilis; all patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis; if infection confirmed, initiate appropriate antibacterial therapy and follow-up tests for these diseases",
          "Local IV site reactions have been reported with IV azithromycin",
          "Prescribing azithromycin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria",
          "Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been reported with macrolides, including azithromycin",
          "Elderly patients may be more susceptible to drug-associated effects on the QT interval",
          "Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens Johnson syndrome, and toxic epidermal necrolysis have been reported",
          "Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported",
          "If an allergic reaction occurs, discontinue drug and institute appropriate therapy",
          "Be aware that allergic symptoms may reappear after symptomatic therapy has been discontinued",
        ]),
    Drug(
        id: 'aasddfzczxczxczxzczxs4dz',
        tradeName: 'AVEROFECTAN 250MG/5ML SUSP. 60 ML',
        genericName: 'CEFDINIR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: '',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasddfzczxc9797zczxs4dz',
        tradeName: 'BACTICEFDIN 125 MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasddfzczzxczxzczxs4dz',
        tradeName: 'CEDENIR 125MG/5ML DRY SUSP.',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasddfzczxc489zxczxzczxs4dz',
        tradeName: 'CEFATHIRD 125MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasddfzczxczx456czxzczxs4dz',
        tradeName: 'CEFDIN 125MG/5ML SUSP. 60ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdaaaaa56czxzczxs4dz',
        tradeName: 'DENROCEF 125MG/5ML SUSP. 60ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasddfzczxczx4kl;lk;56czxzczxs4dz',
        tradeName: 'DINAR 125MG/5ML SUSP. 100ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasddfzczhkhjjlhxczx456czxzczxs4dz',
        tradeName: 'DINAR 125MG/5ML SUSP. 60ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkljzczxs4dz',
        tradeName: 'EGYNIR 125MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkljzczgfdgfdxs4dz',
        tradeName: 'MAXDINIR 125MG/5ML 60ML SUSP',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkljcbvcbczczxs4dz',
        tradeName: 'MAXDINIR 250MG/5ML 60ML SUSP',
        genericName: 'CEFDINIR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkljzwrwerczxs4dz',
        tradeName: 'MERBACTADIN 125MG/5ML DRY SUSP. 60 ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkasdasljzczxs4dz',
        tradeName: 'MERBACTADIN 250MG/5ML DRY SUSP. 60 ML',
        genericName: 'CEFDINIR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkljzczdgdxs4dz',
        tradeName: 'OMNICEF 125MG/5ML SUSP. 40ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkzazcljzczxs4dz',
        tradeName: 'OMNICEF 125MG/5ML SUSP. 80 ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkzazcljzvnvbczxs4dz',
        tradeName: 'RAME-DINIR 125MG/5ML SUSP. 60 ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkzazcljxcvcxzczxs4dz',
        tradeName: 'RAME-DINIR 250MG/5ML SUSP. 60 ML',
        genericName: 'CEFDINIR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkzazclngfhfgjzczxs4dz',
        tradeName: 'SPECTRACEFOCURE 250 MG/5 ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'CEFDINIR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkzagjhgzcljzczxs4dz',
        tradeName: 'TORBENER 125MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'CEFDINIR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'aasdjljkzadsfsfzcljzczxs4dz',
        tradeName: 'TORBENER 250MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'CEFDINIR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote:
            'Iron interferes with cefdinir absorption; administer cefdinir at least 2 hours before or after iron supplements. \n\n Iron-fortified infant formula does not significantly interfere with cefdinir absorption, therefore, cefdinir can be administered with iron-fortified infant formula. \n\n Reddish stools in patients receiving cefdinir have been reported; in many cases, patients were also receiving iron-containing products; reddish color is due to formation of nonabsorbable complex between cefdinir or its breakdown products and iron in GI tract. ',
        prec: [
          "Note differences between twice-daily and once-daily dosing regimens",
          "Use with caution in patients with history of penicillin allergy; if allergic reaction to cefdinir occurs, discontinue therapy",
          "Dosage adjustments may be necessary if CrCl is <30 mL/min",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Use caution in patients with history of colitis",
          "Antacids containing magnesium or aluminum interfere with absorption of cefdinir; if this required during therapy, administer at least 2 hr before or after antacid",
          "Iron supplements, including multivitamins that contain iron, interfere with absorption of cefdinir; if iron supplements required administer at least 2 hours before or after supplement",
        ]),
    Drug(
        id: 'cefaclor2',
        tradeName: 'BACTICLOR 250MG/5ML SUSP. 60ML',
        genericName: 'CEFACLOR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
          "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy",
          "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy",
          "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
        ]),
    Drug(
        id: 'cefaclor1',
        tradeName: 'BACTICLOR 125MG/5ML SUSP. 60ML',
        genericName: 'CEFACLOR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
          "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy",
          "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy",
          "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
        ]),
    Drug(
        id: 'cefaclor3',
        tradeName: 'CECLOR 125MG/5ML SUSP. 75ML',
        genericName: 'CEFACLOR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
          "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy",
          "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy",
          "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
        ]),
    Drug(
        id: 'cefaclor4',
        tradeName: 'CECLOR 250MG/5ML SUSP. 75ML',
        genericName: 'CEFACLOR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
          "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy",
          "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy",
          "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
        ]),
    Drug(
        id: 'cefaclor5',
        tradeName: 'CEFBIOLOR 250MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'CEFACLOR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
          "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy",
          "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy",
          "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
        ]),
    Drug(
        id: 'cefaclor6',
        tradeName: 'CLOROCEF 250MG/5ML SUSP. 60 ML',
        genericName: 'CEFACLOR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
          "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy",
          "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy",
          "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
        ]),
    Drug(
        id: 'cefaclor7',
        tradeName: 'MISACLOR 250MG/5ML PD. FOR ORAL 60ML SUSP.',
        genericName: 'CEFACLOR 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
          "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy",
          "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy",
          "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
        ]),
    Drug(
        id: 'cefaclor8',
        tradeName: 'MISACLOR 125MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'CEFACLOR 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Prescribing drug in absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria",
          "Superinfection (overgrowth by non-susceptible organisms) should always be considered a possibility in patient being treated with broad spectrum antimicrobial; careful observation of patient is essential; take appropriate measures if superinfection occurs during therapy",
          "Reduce dosage by 1/2 if creatinine clearance is 10-30 mL/min, and by 3/4 if <10 mL/min (high doses may cause CNS toxicity); bacterial or fungal overgrowth of non-susceptible organisms may occur with prolonged or repeated therapy",
          "Clostridium difficile associated diarrhea (CDAD) CDAD has been reported with use and may range in severity from mild diarrhea to fatal colitis; treatment with antibacterial agents alters normal flora of colon leading to overgrowth of C. difficile",
        ]),
    Drug(
        id: 'cefadroxil1',
        tradeName: 'BIODROXIL 250MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil2',
        tradeName: 'BIODROXIL 500MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 500MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 500,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil3',
        tradeName: 'CEFADROXIL 250MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil4',
        tradeName: 'CEPHADROL 250 MG/5 ML SUSP. 60 ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil5',
        tradeName: 'CURISAFE 125MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil6',
        tradeName: 'CURISAFE 250MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil7',
        tradeName: 'CURISAFE 500MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 500MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 500,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil8',
        tradeName: 'DURICEF 250 MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil9',
        tradeName: 'DURICEF 500MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 500MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 500,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil10',
        tradeName: 'IBIDROXIL 125MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil11',
        tradeName: 'IBIDROXIL 250 MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil12',
        tradeName: 'IBIDROXIL 500 MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 500MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 500,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil13',
        tradeName: 'LONGICEF 125MG/5ML SUSP. 60 ML',
        genericName: 'CEFADROXIL 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil14',
        tradeName: 'LONGICEF 250MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil15',
        tradeName: 'MEGADROXIL 250MG/5ML ORAL SUSP. 60 ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil16',
        tradeName: 'ROXIL 250MG/5ML SUSP. 100ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefadroxil17',
        tradeName: 'ROXIL 250MG/5ML SUSP. 60ML',
        genericName: 'CEFADROXIL 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Adjust dose in severe renal insufficiency-> (high doses may cause CNS toxicity); prolonged use may result in superinfection",
        ]),
    Drug(
        id: 'cefixim1',
        tradeName: 'BIOCEFIXIM 200MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'CEFIXIME 200MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim2',
        tradeName: 'CEFABRUM 100MG/5ML SUSP. 60ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim3',
        tradeName: 'CEFIXIME 100MG/5ML SUSP. 30ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim4',
        tradeName: 'CEFIXIME 100MG/5ML SUSP. 60ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim5',
        tradeName: 'FLAVICEF 100MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim6',
        tradeName: 'HEBIXIME 100MG/5ML DRY SUSP. 30ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim7',
        tradeName: 'ORACEF 100MG/5ML SUSP. 60ML (N/A)',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim7',
        tradeName: 'ORACEF 100MG/5ML SUSP. 60ML (N/A)',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim8',
        tradeName: 'SUPRAX 100 MG/5 ML SUSP. 30ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim9',
        tradeName: 'SUPRAX 100 MG/5 ML SUSP. 60ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim10',
        tradeName: 'VIODRILNEX 100MG/5ML SUSP. 30ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim11',
        tradeName: 'XIMACEF 100 MG/5ML SUSP. 30ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'cefixim11',
        tradeName: 'XIMACEF 100 MG/5ML SUSP. 60ML',
        genericName: 'CEFIXIME 100MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Dosage must be adjusted in severe renal insufficiency (high doses may cause CNS toxicity, including seizures); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy",
          "Use with caution in patients with history of penicillin allergy",
          "Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Phenylalanine can be harmful to patients with phenylketonuria (PKU); chewable tablets contain aspartame, a source of phenylalanine; before prescribing, consider combined daily amount of phenylalanine from all sources, including chewable tablets",
          "Use caution in patients with history of gastrointestinal disease",
          "Clostridium difficile associated diarrhea (CDAD) reported with use of nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis; if CDAD is suspected or confirmed, discontinue ongoing antibacterial drug use not directed against C. difficile; institute appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation as clinically indicated",
          "Immune-mediated hemolytic anemia reported; monitor hematologic parameters during and for 2 to 3 weeks after therapy; discontinue therapy if hemolytic anemia occurs during treatment",
          "Cephalosporins may be associated with a fall in prothrombin activity; patients with renal or hepatic impairment, or poor nutritional state, patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy; monitor prothrombin time in patients at risk and exogenous vitamin K administered as indicated",
          "May cause acute renal failure including tubulointerstitial nephritis; discontinue therapy if renal failure occurs and initiate supportive therapy",
          "Severe cutaneous reactions, including Stevens-Johnson syndrome, epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) reported; discontinue therapy and implement supportive therapy if reaction occurs",
          "Concomitant use with cefixime and carbamazepine may elevate carbamazepine levels reported in postmarketing experience",
          "Administration of cefixime may result in a false-positive reaction for glucose in the urine using Clinitest®, Benedict’s solution, or Fehling’s solution; use glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or TesTape®) be used",
          "A false-positive direct Coombs test reported during treatment with other cephalosporins; therefore, it should be recognized that a positive Coombs test may be due to the drug",
        ]),
    Drug(
        id: 'clari1',
        tradeName: 'BEDREVIDA 250MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'CLARITHROMYCIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
          "Coadministration with pimozide, cisapride, ergotamine, and dihydroergotamine",
          "History of cholestatic jaundice or hepatic dysfunction associated with previous use of clarithromycin",
          "Coadministration with colchicine in patients with renal or hepatic impairment",
          "Coadministration with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin, simvastatin), due to the increased risk of myopathy, including rhabdomyolysis",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Acute hypersensitivity reactions; discontinue immediately if severe hypersensitivity reactions occur (eg, anaphylaxis, Stevens-Johnson syndrome, TEN, drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome, Henoch-Schonlein purpura)",
          "Associated with QT interval prolongation and infrequent cases of arrhythmias, including torsade de pointes; avoid using with ongoing proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia), clinically significant bradycardia; patients aged ≥65 yr may be more susceptible to drug-associated QT prolongation (also see Drug Interaction Overview)",
          "Hepatic dysfunction, including increased liver enzyme activity and hepatocellular or cholestatic hepatitis, with or without jaundice, have been reported; this may be severe and is usually reversible",
          "Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur (eg, anorexia, jaundice, dark urine, pruritus, tender abdomen)",
          "May increase morbidity among patients with coronary heart disease who received a 2-week course of clarithromycin; in an observational study, this risk became apparent after patients had been followed for ≥1 year; based on this study, the FDA added a warning to the prescribing information (CLARICOR trial; BMJ 2006;332:22-7)",
          "Clostridium difficile associated diarrhea reported with use of nearly all antibacterial agents, including clarithromycin",
          "Not for use in pregnancy, except when there is no alternative therapy; apprise patient about potential hazard to fetus if pregnancy occurs while in therapy",
          "Exacerbation of myasthenia gravis or new onset of symptoms reported",
          "Clarithromycin is a strong CYP3A4 inhibitor and also inhibits P-pg transport (ABCB1)",
          "Clarithromycin is a strong CYP3A4 inhibitor; drugs primarily metabolized by CYP3A4 may result in higher exposure to these medications (also see Contraindications)"
              "Reduce colchicine dose if coadministered with clarithromycin in patients with normal hepatic and renal function (contraindicated with hepatic and renal impairment)",
          "Decrease dose of atorvastatin or pravastatin if coadministered with clarithromycin",
          "Coadministration of clarithromycin with oral hypoglycemic agents and/or insulin can result in significant hypoglycemia; examples of or hypoglycemic agents that are CYP3A substrates include nateglinide, pioglitazone, repaglinide and rosiglitazone",
          "Contraindicated with pimozide with cisapride (each are known to prolong QT interval and are also CYP3A4 substrates)",
          "Avoid coadministration with drugs with known risk of QT prolongation",
          "Coadministration with quetiapine may result in quetiapine related toxicities including neuroleptic malignant syndrome, QT prolongation, somnolence, orthostatic hypotension, altered state of consciousness",
          "Cautiously monitor if coadministered with drugs that may prolong QT interval",
          "Macrolides may increase the serum concentration of vitamin K antagonists (eg, warfarin); monitor INR",
          "Increased and prolonged sedation may occur when coadministered with benzodiazepines (eg, triazolam, midazolam)",
          "May increase digoxin levels via P-gp inhibition",
        ]),
    Drug(
        id: 'clari2',
        tradeName: 'KLACID 125 MG/5 ML SUSP. 70 ML',
        genericName: 'CLARITHROMYCIN 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
          "Coadministration with pimozide, cisapride, ergotamine, and dihydroergotamine",
          "History of cholestatic jaundice or hepatic dysfunction associated with previous use of clarithromycin",
          "Coadministration with colchicine in patients with renal or hepatic impairment",
          "Coadministration with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin, simvastatin), due to the increased risk of myopathy, including rhabdomyolysis",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Acute hypersensitivity reactions; discontinue immediately if severe hypersensitivity reactions occur (eg, anaphylaxis, Stevens-Johnson syndrome, TEN, drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome, Henoch-Schonlein purpura)",
          "Associated with QT interval prolongation and infrequent cases of arrhythmias, including torsade de pointes; avoid using with ongoing proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia), clinically significant bradycardia; patients aged ≥65 yr may be more susceptible to drug-associated QT prolongation (also see Drug Interaction Overview)",
          "Hepatic dysfunction, including increased liver enzyme activity and hepatocellular or cholestatic hepatitis, with or without jaundice, have been reported; this may be severe and is usually reversible",
          "Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur (eg, anorexia, jaundice, dark urine, pruritus, tender abdomen)",
          "May increase morbidity among patients with coronary heart disease who received a 2-week course of clarithromycin; in an observational study, this risk became apparent after patients had been followed for ≥1 year; based on this study, the FDA added a warning to the prescribing information (CLARICOR trial; BMJ 2006;332:22-7)",
          "Clostridium difficile associated diarrhea reported with use of nearly all antibacterial agents, including clarithromycin",
          "Not for use in pregnancy, except when there is no alternative therapy; apprise patient about potential hazard to fetus if pregnancy occurs while in therapy",
          "Exacerbation of myasthenia gravis or new onset of symptoms reported",
          "Clarithromycin is a strong CYP3A4 inhibitor and also inhibits P-pg transport (ABCB1)",
          "Clarithromycin is a strong CYP3A4 inhibitor; drugs primarily metabolized by CYP3A4 may result in higher exposure to these medications (also see Contraindications)"
              "Reduce colchicine dose if coadministered with clarithromycin in patients with normal hepatic and renal function (contraindicated with hepatic and renal impairment)",
          "Decrease dose of atorvastatin or pravastatin if coadministered with clarithromycin",
          "Coadministration of clarithromycin with oral hypoglycemic agents and/or insulin can result in significant hypoglycemia; examples of or hypoglycemic agents that are CYP3A substrates include nateglinide, pioglitazone, repaglinide and rosiglitazone",
          "Contraindicated with pimozide with cisapride (each are known to prolong QT interval and are also CYP3A4 substrates)",
          "Avoid coadministration with drugs with known risk of QT prolongation",
          "Coadministration with quetiapine may result in quetiapine related toxicities including neuroleptic malignant syndrome, QT prolongation, somnolence, orthostatic hypotension, altered state of consciousness",
          "Cautiously monitor if coadministered with drugs that may prolong QT interval",
          "Macrolides may increase the serum concentration of vitamin K antagonists (eg, warfarin); monitor INR",
          "Increased and prolonged sedation may occur when coadministered with benzodiazepines (eg, triazolam, midazolam)",
          "May increase digoxin levels via P-gp inhibition",
        ]),
    Drug(
        id: 'clari3',
        tradeName: 'KLACID 250 MG/5ML SUSP. 70ML',
        genericName: 'CLARITHROMYCIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
          "Coadministration with pimozide, cisapride, ergotamine, and dihydroergotamine",
          "History of cholestatic jaundice or hepatic dysfunction associated with previous use of clarithromycin",
          "Coadministration with colchicine in patients with renal or hepatic impairment",
          "Coadministration with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin, simvastatin), due to the increased risk of myopathy, including rhabdomyolysis",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Acute hypersensitivity reactions; discontinue immediately if severe hypersensitivity reactions occur (eg, anaphylaxis, Stevens-Johnson syndrome, TEN, drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome, Henoch-Schonlein purpura)",
          "Associated with QT interval prolongation and infrequent cases of arrhythmias, including torsade de pointes; avoid using with ongoing proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia), clinically significant bradycardia; patients aged ≥65 yr may be more susceptible to drug-associated QT prolongation (also see Drug Interaction Overview)",
          "Hepatic dysfunction, including increased liver enzyme activity and hepatocellular or cholestatic hepatitis, with or without jaundice, have been reported; this may be severe and is usually reversible",
          "Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur (eg, anorexia, jaundice, dark urine, pruritus, tender abdomen)",
          "May increase morbidity among patients with coronary heart disease who received a 2-week course of clarithromycin; in an observational study, this risk became apparent after patients had been followed for ≥1 year; based on this study, the FDA added a warning to the prescribing information (CLARICOR trial; BMJ 2006;332:22-7)",
          "Clostridium difficile associated diarrhea reported with use of nearly all antibacterial agents, including clarithromycin",
          "Not for use in pregnancy, except when there is no alternative therapy; apprise patient about potential hazard to fetus if pregnancy occurs while in therapy",
          "Exacerbation of myasthenia gravis or new onset of symptoms reported",
          "Clarithromycin is a strong CYP3A4 inhibitor and also inhibits P-pg transport (ABCB1)",
          "Clarithromycin is a strong CYP3A4 inhibitor; drugs primarily metabolized by CYP3A4 may result in higher exposure to these medications (also see Contraindications)"
              "Reduce colchicine dose if coadministered with clarithromycin in patients with normal hepatic and renal function (contraindicated with hepatic and renal impairment)",
          "Decrease dose of atorvastatin or pravastatin if coadministered with clarithromycin",
          "Coadministration of clarithromycin with oral hypoglycemic agents and/or insulin can result in significant hypoglycemia; examples of or hypoglycemic agents that are CYP3A substrates include nateglinide, pioglitazone, repaglinide and rosiglitazone",
          "Contraindicated with pimozide with cisapride (each are known to prolong QT interval and are also CYP3A4 substrates)",
          "Avoid coadministration with drugs with known risk of QT prolongation",
          "Coadministration with quetiapine may result in quetiapine related toxicities including neuroleptic malignant syndrome, QT prolongation, somnolence, orthostatic hypotension, altered state of consciousness",
          "Cautiously monitor if coadministered with drugs that may prolong QT interval",
          "Macrolides may increase the serum concentration of vitamin K antagonists (eg, warfarin); monitor INR",
          "Increased and prolonged sedation may occur when coadministered with benzodiazepines (eg, triazolam, midazolam)",
          "May increase digoxin levels via P-gp inhibition",
        ]),
    Drug(
        id: 'clari4',
        tradeName: 'KLARIMIX 125MG/5ML SUSP. 60ML',
        genericName: 'CLARITHROMYCIN 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
          "Coadministration with pimozide, cisapride, ergotamine, and dihydroergotamine",
          "History of cholestatic jaundice or hepatic dysfunction associated with previous use of clarithromycin",
          "Coadministration with colchicine in patients with renal or hepatic impairment",
          "Coadministration with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin, simvastatin), due to the increased risk of myopathy, including rhabdomyolysis",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Acute hypersensitivity reactions; discontinue immediately if severe hypersensitivity reactions occur (eg, anaphylaxis, Stevens-Johnson syndrome, TEN, drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome, Henoch-Schonlein purpura)",
          "Associated with QT interval prolongation and infrequent cases of arrhythmias, including torsade de pointes; avoid using with ongoing proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia), clinically significant bradycardia; patients aged ≥65 yr may be more susceptible to drug-associated QT prolongation (also see Drug Interaction Overview)",
          "Hepatic dysfunction, including increased liver enzyme activity and hepatocellular or cholestatic hepatitis, with or without jaundice, have been reported; this may be severe and is usually reversible",
          "Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur (eg, anorexia, jaundice, dark urine, pruritus, tender abdomen)",
          "May increase morbidity among patients with coronary heart disease who received a 2-week course of clarithromycin; in an observational study, this risk became apparent after patients had been followed for ≥1 year; based on this study, the FDA added a warning to the prescribing information (CLARICOR trial; BMJ 2006;332:22-7)",
          "Clostridium difficile associated diarrhea reported with use of nearly all antibacterial agents, including clarithromycin",
          "Not for use in pregnancy, except when there is no alternative therapy; apprise patient about potential hazard to fetus if pregnancy occurs while in therapy",
          "Exacerbation of myasthenia gravis or new onset of symptoms reported",
          "Clarithromycin is a strong CYP3A4 inhibitor and also inhibits P-pg transport (ABCB1)",
          "Clarithromycin is a strong CYP3A4 inhibitor; drugs primarily metabolized by CYP3A4 may result in higher exposure to these medications (also see Contraindications)"
              "Reduce colchicine dose if coadministered with clarithromycin in patients with normal hepatic and renal function (contraindicated with hepatic and renal impairment)",
          "Decrease dose of atorvastatin or pravastatin if coadministered with clarithromycin",
          "Coadministration of clarithromycin with oral hypoglycemic agents and/or insulin can result in significant hypoglycemia; examples of or hypoglycemic agents that are CYP3A substrates include nateglinide, pioglitazone, repaglinide and rosiglitazone",
          "Contraindicated with pimozide with cisapride (each are known to prolong QT interval and are also CYP3A4 substrates)",
          "Avoid coadministration with drugs with known risk of QT prolongation",
          "Coadministration with quetiapine may result in quetiapine related toxicities including neuroleptic malignant syndrome, QT prolongation, somnolence, orthostatic hypotension, altered state of consciousness",
          "Cautiously monitor if coadministered with drugs that may prolong QT interval",
          "Macrolides may increase the serum concentration of vitamin K antagonists (eg, warfarin); monitor INR",
          "Increased and prolonged sedation may occur when coadministered with benzodiazepines (eg, triazolam, midazolam)",
          "May increase digoxin levels via P-gp inhibition",
        ]),
    Drug(
        id: 'clari5',
        tradeName: 'KLARIMIX 250MG/5ML SUSP. 60ML',
        genericName: 'CLARITHROMYCIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Documented hypersensitivity",
          "Coadministration with pimozide, cisapride, ergotamine, and dihydroergotamine",
          "History of cholestatic jaundice or hepatic dysfunction associated with previous use of clarithromycin",
          "Coadministration with colchicine in patients with renal or hepatic impairment",
          "Coadministration with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin, simvastatin), due to the increased risk of myopathy, including rhabdomyolysis",
        ],
        conc: 5 / 250,
        minD: 0,
        maxD: 0,
        freq: 'PO q12h for 10-14 days',
        doseNote: '',
        prec: [
          "Acute hypersensitivity reactions; discontinue immediately if severe hypersensitivity reactions occur (eg, anaphylaxis, Stevens-Johnson syndrome, TEN, drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome, Henoch-Schonlein purpura)",
          "Associated with QT interval prolongation and infrequent cases of arrhythmias, including torsade de pointes; avoid using with ongoing proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia), clinically significant bradycardia; patients aged ≥65 yr may be more susceptible to drug-associated QT prolongation (also see Drug Interaction Overview)",
          "Hepatic dysfunction, including increased liver enzyme activity and hepatocellular or cholestatic hepatitis, with or without jaundice, have been reported; this may be severe and is usually reversible",
          "Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur (eg, anorexia, jaundice, dark urine, pruritus, tender abdomen)",
          "May increase morbidity among patients with coronary heart disease who received a 2-week course of clarithromycin; in an observational study, this risk became apparent after patients had been followed for ≥1 year; based on this study, the FDA added a warning to the prescribing information (CLARICOR trial; BMJ 2006;332:22-7)",
          "Clostridium difficile associated diarrhea reported with use of nearly all antibacterial agents, including clarithromycin",
          "Not for use in pregnancy, except when there is no alternative therapy; apprise patient about potential hazard to fetus if pregnancy occurs while in therapy",
          "Exacerbation of myasthenia gravis or new onset of symptoms reported",
          "Clarithromycin is a strong CYP3A4 inhibitor and also inhibits P-pg transport (ABCB1)",
          "Clarithromycin is a strong CYP3A4 inhibitor; drugs primarily metabolized by CYP3A4 may result in higher exposure to these medications (also see Contraindications)"
              "Reduce colchicine dose if coadministered with clarithromycin in patients with normal hepatic and renal function (contraindicated with hepatic and renal impairment)",
          "Decrease dose of atorvastatin or pravastatin if coadministered with clarithromycin",
          "Coadministration of clarithromycin with oral hypoglycemic agents and/or insulin can result in significant hypoglycemia; examples of or hypoglycemic agents that are CYP3A substrates include nateglinide, pioglitazone, repaglinide and rosiglitazone",
          "Contraindicated with pimozide with cisapride (each are known to prolong QT interval and are also CYP3A4 substrates)",
          "Avoid coadministration with drugs with known risk of QT prolongation",
          "Coadministration with quetiapine may result in quetiapine related toxicities including neuroleptic malignant syndrome, QT prolongation, somnolence, orthostatic hypotension, altered state of consciousness",
          "Cautiously monitor if coadministered with drugs that may prolong QT interval",
          "Macrolides may increase the serum concentration of vitamin K antagonists (eg, warfarin); monitor INR",
          "Increased and prolonged sedation may occur when coadministered with benzodiazepines (eg, triazolam, midazolam)",
          "May increase digoxin levels via P-gp inhibition",
        ]),
    Drug(
        id: 'ceflexin1',
        tradeName: 'AMTHROST 125MG/5ML SUSP. 60ML',
        genericName: 'CEFALEXIN 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 125,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin2',
        tradeName: 'AMTHROST 250MG/5ML SUSP. 60ML',
        genericName: 'CEFALEXIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 250,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin3',
        tradeName: 'CEPHALEXIN 250MG/5ML SUSP. 60ML USP24',
        genericName: 'CEFALEXIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 250,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin4',
        tradeName: 'CEPHLEX 125MG/5ML SUSP. 60ML',
        genericName: 'CEFALEXIN 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 125,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin5',
        tradeName: 'CEPHLEX 250 MG/5 ML SUSP. 60ML',
        genericName: 'CEFALEXIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 250,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin6',
        tradeName: 'CEPHOXIN 125MG/5ML DRY SUSP. 60 ML',
        genericName: 'CEFALEXIN 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 125,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin7',
        tradeName: 'CEPHOXIN 250MG/5ML DRY SUSP. 60 ML',
        genericName: 'CEFALEXIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 250,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin8',
        tradeName: 'CEPOREX 125MG /5ML SUSP. 60ML',
        genericName: 'CEFALEXIN 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 125,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin9',
        tradeName: 'KEFLEX 250MG/5ML PD. FOR ORAL SUSP.60ML',
        genericName: 'CEFALEXIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 250,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin10',
        tradeName: 'MEDICEFLEXIN 250MG/5ML SUSP. 100ML',
        genericName: 'CEFALEXIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 250,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin11',
        tradeName: 'OSPEXIN 125MG/5ML SUSP. 60ML',
        genericName: 'CEFALEXIN 125MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 125,
        minD: 8.33,
        maxD: 16.66,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'ceflexin12',
        tradeName: 'OSPEXIN 250MG/5ML SUSP. 60ML',
        genericName: 'CEFALEXIN 250MG/5ML SUSP',
        cat: 'Antibiotics',
        contra: [
          "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Cefalexin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.",
        ],
        conc: 5 / 250,
        minD: 25,
        maxD: 50,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Before instituting therapy with cefalexin, every effort should be made to determine whether the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins or other drugs. Cefalexin should be given cautiously to penicillin-sensitive patients. There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and cephalosporins. Patients have had severe reactions (including anaphylaxis) to both drugs.",
          "Pseudomembranous colitis has been reported with virtually all broad-spectrum antibiotics, including macrolides, semisynthetic penicillins and cephalosporins. It is important, therefore, to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Such colitis may range in severity from mild to life-threatening. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken.",
          "If an allergic reaction to cefalexin occurs, the drug should be discontinued and the patient treated with the appropriate agents.",
          "Prolonged use of cefalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.",
          "Cefalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended. If dialysis is required for renal failure, the daily dose of cefalexin should not exceed 500mg.",
          "Concurrent administration with certain other drug substances, such as aminoglycosides, other cephalosporins, or furosemide, (frusemide) and similar potent diuretics, may increase the risk of nephrotoxicity.",
          "Positive direct Coombs' tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies, or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side, or in Coombs' testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs' test may be due to the drug.",
          "A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.",
          "Acute generalised exanthematous pustulosis (AGEP) has been reported in association with cefalexin treatment. At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefalexin should be withdrawn immediately and an alternative treatment considered. Most of these reactions occurred most likely in the first week during treatment.",
        ]),
    Drug(
        id: 'metro1',
        tradeName: 'AMRIZOLE 125MG/5ML SUSP. 120ML',
        genericName: 'METRONIDAZOLE 125MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
          "Seizures and aseptic meningitis reported with increase in dose and chronic therapy",
          "Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) reported with metronidazole",
          "Encephalopathy reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria; CNS lesions seen on MRI described in reports of encephalopathy; CNS symptoms are generally reversible within days to weeks upon discontinuation of therapy; lesions seen on MRI have also been described as reversible",
          "Peripheral neuropathy, mainly of sensory type reported and characterized by numbness or paresthesia of an extremity",
          "Prescribing metronidazole tablets in absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria and parasites",
          "Superinfection may occur with prolonged use",
          "Severe hepatic impairment; administer lower doses with caution",
          "Use with caution; potential accumulation in end stage renal disease; supplemental doses may be needed in patients receiving hemodialysis",
          "Use with caution in history of heart failure, hepatic failure, H. pylori infection, renal impairment",
          "Use with care in patients with evidence of or history of blood dyscrasia; agranulocytosis, leukopenia and neutropenia have been associated with metronidazole administration; monitor complete blood count;monitor complete blood count (CBC) for leukopenia before, during, and after prolonged repeated therapy",
        ]),
    Drug(
        id: 'metro2',
        tradeName: 'DUMOZOL 125MG/5ML SUSP. 125ML',
        genericName: 'METRONIDAZOLE 125MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
          "Seizures and aseptic meningitis reported with increase in dose and chronic therapy",
          "Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) reported with metronidazole",
          "Encephalopathy reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria; CNS lesions seen on MRI described in reports of encephalopathy; CNS symptoms are generally reversible within days to weeks upon discontinuation of therapy; lesions seen on MRI have also been described as reversible",
          "Peripheral neuropathy, mainly of sensory type reported and characterized by numbness or paresthesia of an extremity",
          "Prescribing metronidazole tablets in absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria and parasites",
          "Superinfection may occur with prolonged use",
          "Severe hepatic impairment; administer lower doses with caution",
          "Use with caution; potential accumulation in end stage renal disease; supplemental doses may be needed in patients receiving hemodialysis",
          "Use with caution in history of heart failure, hepatic failure, H. pylori infection, renal impairment",
          "Use with care in patients with evidence of or history of blood dyscrasia; agranulocytosis, leukopenia and neutropenia have been associated with metronidazole administration; monitor complete blood count;monitor complete blood count (CBC) for leukopenia before, during, and after prolonged repeated therapy",
        ]),
    Drug(
        id: 'metro3',
        tradeName: 'ENTOPHAR 125MG/5ML SUSP. 120ML',
        genericName: 'METRONIDAZOLE 125MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
          "Seizures and aseptic meningitis reported with increase in dose and chronic therapy",
          "Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) reported with metronidazole",
          "Encephalopathy reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria; CNS lesions seen on MRI described in reports of encephalopathy; CNS symptoms are generally reversible within days to weeks upon discontinuation of therapy; lesions seen on MRI have also been described as reversible",
          "Peripheral neuropathy, mainly of sensory type reported and characterized by numbness or paresthesia of an extremity",
          "Prescribing metronidazole tablets in absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria and parasites",
          "Superinfection may occur with prolonged use",
          "Severe hepatic impairment; administer lower doses with caution",
          "Use with caution; potential accumulation in end stage renal disease; supplemental doses may be needed in patients receiving hemodialysis",
          "Use with caution in history of heart failure, hepatic failure, H. pylori infection, renal impairment",
          "Use with care in patients with evidence of or history of blood dyscrasia; agranulocytosis, leukopenia and neutropenia have been associated with metronidazole administration; monitor complete blood count;monitor complete blood count (CBC) for leukopenia before, during, and after prolonged repeated therapy",
        ]),
    Drug(
        id: 'metro4',
        tradeName: 'FLAGELLAT FORTE 200MG/5ML SUSP. 100 ML',
        genericName: 'METRONIDAZOLE 200MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
        ],
        conc: 5 / 200,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
          "Seizures and aseptic meningitis reported with increase in dose and chronic therapy",
          "Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) reported with metronidazole",
          "Encephalopathy reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria; CNS lesions seen on MRI described in reports of encephalopathy; CNS symptoms are generally reversible within days to weeks upon discontinuation of therapy; lesions seen on MRI have also been described as reversible",
          "Peripheral neuropathy, mainly of sensory type reported and characterized by numbness or paresthesia of an extremity",
          "Prescribing metronidazole tablets in absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria and parasites",
          "Superinfection may occur with prolonged use",
          "Severe hepatic impairment; administer lower doses with caution",
          "Use with caution; potential accumulation in end stage renal disease; supplemental doses may be needed in patients receiving hemodialysis",
          "Use with caution in history of heart failure, hepatic failure, H. pylori infection, renal impairment",
          "Use with care in patients with evidence of or history of blood dyscrasia; agranulocytosis, leukopenia and neutropenia have been associated with metronidazole administration; monitor complete blood count;monitor complete blood count (CBC) for leukopenia before, during, and after prolonged repeated therapy",
        ]),
    Drug(
        id: 'metro5',
        tradeName: 'FLAGYL 125MG/5ML SUSP. 100ML',
        genericName: 'METRONIDAZOLE 125MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
          "Seizures and aseptic meningitis reported with increase in dose and chronic therapy",
          "Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) reported with metronidazole",
          "Encephalopathy reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria; CNS lesions seen on MRI described in reports of encephalopathy; CNS symptoms are generally reversible within days to weeks upon discontinuation of therapy; lesions seen on MRI have also been described as reversible",
          "Peripheral neuropathy, mainly of sensory type reported and characterized by numbness or paresthesia of an extremity",
          "Prescribing metronidazole tablets in absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria and parasites",
          "Superinfection may occur with prolonged use",
          "Severe hepatic impairment; administer lower doses with caution",
          "Use with caution; potential accumulation in end stage renal disease; supplemental doses may be needed in patients receiving hemodialysis",
          "Use with caution in history of heart failure, hepatic failure, H. pylori infection, renal impairment",
          "Use with care in patients with evidence of or history of blood dyscrasia; agranulocytosis, leukopenia and neutropenia have been associated with metronidazole administration; monitor complete blood count;monitor complete blood count (CBC) for leukopenia before, during, and after prolonged repeated therapy",
        ]),
    Drug(
        id: 'metro6',
        tradeName: 'METROZOLE 125MG/5ML SUSP. 120 ML',
        genericName: 'METRONIDAZOLE 125MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
        ],
        conc: 5 / 125,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Hypersensitivity to metronidazole or other nitroimidazoles (although cautious desensitization has been applied)",
          "Pregnancy, 1st trimester in patients with trichomoniasis",
          "Use of disulfiram within past 2 weeks; use of alcohol during therapy or within 3 days of discontinuing therapy",
          "Seizures and aseptic meningitis reported with increase in dose and chronic therapy",
          "Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) reported with metronidazole",
          "Encephalopathy reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria; CNS lesions seen on MRI described in reports of encephalopathy; CNS symptoms are generally reversible within days to weeks upon discontinuation of therapy; lesions seen on MRI have also been described as reversible",
          "Peripheral neuropathy, mainly of sensory type reported and characterized by numbness or paresthesia of an extremity",
          "Prescribing metronidazole tablets in absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria and parasites",
          "Superinfection may occur with prolonged use",
          "Severe hepatic impairment; administer lower doses with caution",
          "Use with caution; potential accumulation in end stage renal disease; supplemental doses may be needed in patients receiving hemodialysis",
          "Use with caution in history of heart failure, hepatic failure, H. pylori infection, renal impairment",
          "Use with care in patients with evidence of or history of blood dyscrasia; agranulocytosis, leukopenia and neutropenia have been associated with metronidazole administration; monitor complete blood count;monitor complete blood count (CBC) for leukopenia before, during, and after prolonged repeated therapy",
        ]),
    Drug(
        id: 'nita1',
        tradeName: 'CRYPTONAZ 100MG/5ML SUSP. 60ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita2',
        tradeName: 'CRYPTOPER 100MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita3',
        tradeName: 'EGYGASTREAZ 100MG/5ML PD. FOR ORAL 60ML SUSP.',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita4',
        tradeName: 'NANAZOXID 100MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita5',
        tradeName: 'NIT CLEAN 100MG/5ML PD. FOR ORAL SUSP. 60 ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita6',
        tradeName: 'NITAZODE 100MG/5ML 60ML SUSP.',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita7',
        tradeName: 'NITAZOXIN 100MG/5ML PD. FOR ORAL SUSP. 60ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita8',
        tradeName: 'TRUSTNAL 100MG/5ML ORAL SUSP. 100 ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita9',
        tradeName: 'TRUSTNAL 100MG/5ML ORAL SUSP. 100 ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita10',
        tradeName: 'UNINITAPROZAX 100MG/5ML SUSP. 60ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'nita11',
        tradeName: 'ZOLIFUTAL 100MG/5ML SUSP. 60 ML',
        genericName: 'NITAZOXANIDE 100MG/5ML SUSP',
        cat: 'GIT',
        contra: [
          "Hypersensitivity ",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Safety and efficacy not established in HIV+ or immunodeficient patients",
          "Effects in hepatic/renal impairment unknown; use caution",
          "Safety and efficacy of suspension in children <1 year not established",
          "Safety and efficacy of tablets in children <12 years not established",
        ]),
    Drug(
        id: 'sme1',
        tradeName: 'DIASMECT 20% SUSP. 60ML',
        genericName: 'DIOCTAHEDRAL SMECTITE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to diosmectite or to one of the excipients.Due to the presence of glucose and saccharose, this medication is contraindicated for patients who are fructose intolerant.",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "The diosmectite must be used carefully by patients with history of severe chronic constipation.In children, acute diarrhea must be treated in association with the early administration of an oral rehydration solution (ORS) to avoid dehydration.In adults, the treatment does not dispense with rehydration, if this is considered to be necessary.The amount of rehydration by oral rehydration solution or intravenously must be adapted to the intensity of the diarrhea, and the patient's age and characteristics.The patient must be informed of the need to: Rehydrate with plenty of salty or sweet fluids, to make up for the loss of fluid, due to the diarrhea (the daily mean intake of water for an adult is 2 liters); keep up his/her food intake during the bout of diarrhea: Excluding certain supplements and, in particular, raw vegetables, fruit, green vegetables, spicy food and frozen foods and drinks, and eating grilled meats and rice.",
        ]),
    Drug(
        id: 'sme2',
        tradeName: 'DIOMACTE 20% SUSP. 60 ML',
        genericName: 'DIOCTAHEDRAL SMECTITE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to diosmectite or to one of the excipients.Due to the presence of glucose and saccharose, this medication is contraindicated for patients who are fructose intolerant.",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "The diosmectite must be used carefully by patients with history of severe chronic constipation.In children, acute diarrhea must be treated in association with the early administration of an oral rehydration solution (ORS) to avoid dehydration.In adults, the treatment does not dispense with rehydration, if this is considered to be necessary.The amount of rehydration by oral rehydration solution or intravenously must be adapted to the intensity of the diarrhea, and the patient's age and characteristics.The patient must be informed of the need to: Rehydrate with plenty of salty or sweet fluids, to make up for the loss of fluid, due to the diarrhea (the daily mean intake of water for an adult is 2 liters); keep up his/her food intake during the bout of diarrhea: Excluding certain supplements and, in particular, raw vegetables, fruit, green vegetables, spicy food and frozen foods and drinks, and eating grilled meats and rice.",
        ]),
    Drug(
        id: 'sme3',
        tradeName: 'SMECTA 20% SUSPENSION 120 ML',
        genericName: 'DIOCTAHEDRAL SMECTITE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to diosmectite or to one of the excipients.Due to the presence of glucose and saccharose, this medication is contraindicated for patients who are fructose intolerant.",
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "The diosmectite must be used carefully by patients with history of severe chronic constipation.In children, acute diarrhea must be treated in association with the early administration of an oral rehydration solution (ORS) to avoid dehydration.In adults, the treatment does not dispense with rehydration, if this is considered to be necessary.The amount of rehydration by oral rehydration solution or intravenously must be adapted to the intensity of the diarrhea, and the patient's age and characteristics.The patient must be informed of the need to: Rehydrate with plenty of salty or sweet fluids, to make up for the loss of fluid, due to the diarrhea (the daily mean intake of water for an adult is 2 liters); keep up his/her food intake during the bout of diarrhea: Excluding certain supplements and, in particular, raw vegetables, fruit, green vegetables, spicy food and frozen foods and drinks, and eating grilled meats and rice.",
        ]),
    Drug(
        id: 'kao1',
        tradeName: 'KAPECT SUSP. 120 ML',
        genericName: 'KAOLIN+PECTIN',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients",
          "Pseudomembranous colitis",
          'Obstructive bowel lesion'
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Not to be used for self medication of diarrhea for > 48 hours or for diarrhea associated with pseudomembranous enterocolitis or toxigenic bacteria.",
        ]),
    Drug(
        id: 'kao2',
        tradeName: 'PECTOKAL 100ML SUSP.',
        genericName: 'KAOLIN+PECTIN',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients",
          "Pseudomembranous colitis",
          'Obstructive bowel lesion'
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Not to be used for self medication of diarrhea for > 48 hours or for diarrhea associated with pseudomembranous enterocolitis or toxigenic bacteria.",
        ]),
    Drug(
        id: 'nifur1',
        tradeName: 'ANTINAL 220MG/5ML 60ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur2',
        tradeName: 'DIA-FURYL 220MG/5ML ORAL SUSP. 60 ML',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur3',
        tradeName: 'DIAX 220MG/5ML 60ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur4',
        tradeName: 'FLATROLAM 220MG/5ML SUSP. 100ML',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur5',
        tradeName: 'FURFURIL 220MG/5ML ORAL 60ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur6',
        tradeName: 'INTEST-RELIEF 220MG/5ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur7',
        tradeName: 'NIFUNAL 4% 90ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur8',
        tradeName: 'NIFUNAZIDE 220MG/5ML SUSP. 60 ML',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur9',
        tradeName: 'NIFUROX 200MG/5ML 100ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur10',
        tradeName: 'NIFUROXAZIDE 220MG/5ML 60ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur11',
        tradeName: 'NITROFURINAL 220MG/5ML 60ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'nifur12',
        tradeName: 'PANAX DIARREX 200MG/5ML ORAL 120ML SUSP.',
        genericName: 'NIFUROXAZIDE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to nitrofuran derivatives or any of the other components."
        ],
        conc: 5 / 100,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Rehydration is the essential treatment for acute diarrhoea in infants below the age of 2 years. In children over this age, it should always be considered.",
          "If diarrhoea persists after two days of treatment, management should be reviewed and the need for oral or intravenous rehydration should be considered.",
          "In case of severe prolonged diarrhoea, severe vomiting or refusal to eat, intravenous rehydration should be considered.",
          "In the event of infectious diarrhoea, with clinical signs and symptoms suggestive of an invasive phenomenon, antibacterial agents with good systemic diffusion should be employed.",
        ]),
    Drug(
        id: 'trim1',
        tradeName: 'GAST-REG  24MG/5ML 125ML SUSP.',
        genericName: 'TRIMEBUTINE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to trimebutine derivatives or any of the other components."
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Common gastrointestinal adverse effects include dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea and constipation. Some CNS effects include drowsiness, fatigue, dizziness, hot/cold sensations and headaches. In case of overdosage, gastric lavage is recommended. Oral LD50 in mouse and rats is >5000 mg/kg and 2500 mg/kg in rabbits, respectively. Trimebutine is not reported to display teratogenic, mutagenic or carcinogenic potential ",
        ]),
    Drug(
        id: 'trim2',
        tradeName: 'G-REGULATOR 24MG/5ML 125ML SUSP',
        genericName: 'TRIMEBUTINE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to trimebutine derivatives or any of the other components."
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Common gastrointestinal adverse effects include dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea and constipation. Some CNS effects include drowsiness, fatigue, dizziness, hot/cold sensations and headaches. In case of overdosage, gastric lavage is recommended. Oral LD50 in mouse and rats is >5000 mg/kg and 2500 mg/kg in rabbits, respectively. Trimebutine is not reported to display teratogenic, mutagenic or carcinogenic potential ",
        ]),
    Drug(
        id: 'trim3',
        tradeName: 'TRITONE 4.8MG/ML SUSP. 125ML',
        genericName: 'TRIMEBUTINE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to trimebutine derivatives or any of the other components."
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Common gastrointestinal adverse effects include dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea and constipation. Some CNS effects include drowsiness, fatigue, dizziness, hot/cold sensations and headaches. In case of overdosage, gastric lavage is recommended. Oral LD50 in mouse and rats is >5000 mg/kg and 2500 mg/kg in rabbits, respectively. Trimebutine is not reported to display teratogenic, mutagenic or carcinogenic potential ",
        ]),
    Drug(
        id: 'cara1',
        tradeName: 'CALMA KING SYRUP 120 ML',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara2',
        tradeName: 'FREE BABY SYRUP 120 ML',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara3',
        tradeName: 'NONO WATER SYRUP 120 ML',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara4',
        tradeName: 'AQUA CID SYRUP 120ML',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara5',
        tradeName: 'AQUA CURE SYRUP 120 ML',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara6',
        tradeName: 'AQUA PLUS SYRUP 100 ML',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara7',
        tradeName: 'AQUA REAM SYRUP 120 ML',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara8',
        tradeName: 'Calma king syrup 120 ml',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara9',
        tradeName: 'Carminex syrup 120 ml',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara10',
        tradeName: 'Cid water syrup 120 ml',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara11',
        tradeName: 'free baby syrup 120 ml',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara12',
        tradeName: 'Nono water syrup 120 ml',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara13',
        tradeName: 'Pedi water syrup 120 ml',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'cara14',
        tradeName: 'Gripe water syrup 120 ml',
        genericName: 'CARAWAY OIL+DILL OIL+SODIUM BICARBONATE',
        cat: 'GIT',
        contra: [
          "Hypersensitivity to the active ingredients or any of the other components.",
          "Severe renal impairment",
          "Galstones",
          "Chronic heart failure"
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Patients with rare herediatery problems of fructose intolerance should not take this medicines",
        ]),
    Drug(
        id: 'domp1',
        tradeName: 'DOMPIDONE 100MG/100ML ORAL SUSP. 100ML',
        genericName: 'DOMPERIDONE 100MG/100ML ORAL SUSP',
        cat: 'GIT',
        contra: [
          " Known hypersensitivity to domperidone or any of the excipients",
          " Prolactin-releasing pituitary tumour (prolactinoma).",
          " when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          " in patients with moderate or severe hepatic impairment",
          " in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          " co-administration with QT-prolonging drugs, at the exception of apomorphine",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Known hypersensitivity to domperidone or any of the excipients",
          "Prolactin-releasing pituitary tumour (prolactinoma).",
          "when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          "in patients with moderate or severe hepatic impairment",
          "in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
          "Domperidone has been associated with prolongation of the QT interval on the electrocardiogram. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking domperidone. These reports included patients with confounding risk factors, electrolyte abnormalities and concomitant treatment which may have been contributing factors",
          "Epidemiological studies showed that domperidone was associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death (see section 4.8). A higher risk was observed in patients older than 60 years, patients taking daily doses greater than 30 mg, and patients concurrently taking QT-prolonging drugs or CYP3A4 inhibitors.",
          "Domperidone should be used at the lowest effective dose in adults and adolescents 12 years of age and older.",
          "Domperidone is contraindicated in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure due to increased risk of ventricular arrhythmia (see section 4.3.). Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) or bradycardia are known to be conditions increasing the proarrythmic risk.",
          "Treatment with domperidone should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patients should consult their physician.",
          "Patients should be advised to promptly report any cardiac symptoms.",
          "The oral suspension contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. The oral suspension includes propylhydroxybenzoate (E216) and methylhydroxybenzoate (E218) which may cause allergic reactions (possibly delayed).",
        ]),
    Drug(
        id: 'domp2',
        tradeName: 'FARCOTILIUM 1MG/ML SUSP. 120ML',
        genericName: 'DOMPERIDONE 100MG/100ML ORAL SUSP',
        cat: 'GIT',
        contra: [
          " Known hypersensitivity to domperidone or any of the excipients",
          " Prolactin-releasing pituitary tumour (prolactinoma).",
          " when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          " in patients with moderate or severe hepatic impairment",
          " in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          " co-administration with QT-prolonging drugs, at the exception of apomorphine",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Known hypersensitivity to domperidone or any of the excipients",
          "Prolactin-releasing pituitary tumour (prolactinoma).",
          "when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          "in patients with moderate or severe hepatic impairment",
          "in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
          "Domperidone has been associated with prolongation of the QT interval on the electrocardiogram. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking domperidone. These reports included patients with confounding risk factors, electrolyte abnormalities and concomitant treatment which may have been contributing factors",
          "Epidemiological studies showed that domperidone was associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death (see section 4.8). A higher risk was observed in patients older than 60 years, patients taking daily doses greater than 30 mg, and patients concurrently taking QT-prolonging drugs or CYP3A4 inhibitors.",
          "Domperidone should be used at the lowest effective dose in adults and adolescents 12 years of age and older.",
          "Domperidone is contraindicated in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure due to increased risk of ventricular arrhythmia (see section 4.3.). Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) or bradycardia are known to be conditions increasing the proarrythmic risk.",
          "Treatment with domperidone should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patients should consult their physician.",
          "Patients should be advised to promptly report any cardiac symptoms.",
          "The oral suspension contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. The oral suspension includes propylhydroxybenzoate (E216) and methylhydroxybenzoate (E218) which may cause allergic reactions (possibly delayed).",
        ]),
    Drug(
        id: 'domp3',
        tradeName: 'GASTROMOTIL 1MG/ML ORAL SUSP. 200ML',
        genericName: 'DOMPERIDONE 100MG/100ML ORAL SUSP',
        cat: 'GIT',
        contra: [
          " Known hypersensitivity to domperidone or any of the excipients",
          " Prolactin-releasing pituitary tumour (prolactinoma).",
          " when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          " in patients with moderate or severe hepatic impairment",
          " in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          " co-administration with QT-prolonging drugs, at the exception of apomorphine",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Known hypersensitivity to domperidone or any of the excipients",
          "Prolactin-releasing pituitary tumour (prolactinoma).",
          "when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          "in patients with moderate or severe hepatic impairment",
          "in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
          "Domperidone has been associated with prolongation of the QT interval on the electrocardiogram. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking domperidone. These reports included patients with confounding risk factors, electrolyte abnormalities and concomitant treatment which may have been contributing factors",
          "Epidemiological studies showed that domperidone was associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death (see section 4.8). A higher risk was observed in patients older than 60 years, patients taking daily doses greater than 30 mg, and patients concurrently taking QT-prolonging drugs or CYP3A4 inhibitors.",
          "Domperidone should be used at the lowest effective dose in adults and adolescents 12 years of age and older.",
          "Domperidone is contraindicated in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure due to increased risk of ventricular arrhythmia (see section 4.3.). Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) or bradycardia are known to be conditions increasing the proarrythmic risk.",
          "Treatment with domperidone should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patients should consult their physician.",
          "Patients should be advised to promptly report any cardiac symptoms.",
          "The oral suspension contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. The oral suspension includes propylhydroxybenzoate (E216) and methylhydroxybenzoate (E218) which may cause allergic reactions (possibly delayed).",
        ]),
    Drug(
        id: 'domp4',
        tradeName: 'MOTILIUM 1MG/ML SUSP. 100ML',
        genericName: 'DOMPERIDONE 100MG/100ML ORAL SUSP',
        cat: 'GIT',
        contra: [
          " Known hypersensitivity to domperidone or any of the excipients",
          " Prolactin-releasing pituitary tumour (prolactinoma).",
          " when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          " in patients with moderate or severe hepatic impairment",
          " in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          " co-administration with QT-prolonging drugs, at the exception of apomorphine",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Known hypersensitivity to domperidone or any of the excipients",
          "Prolactin-releasing pituitary tumour (prolactinoma).",
          "when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          "in patients with moderate or severe hepatic impairment",
          "in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
          "Domperidone has been associated with prolongation of the QT interval on the electrocardiogram. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking domperidone. These reports included patients with confounding risk factors, electrolyte abnormalities and concomitant treatment which may have been contributing factors",
          "Epidemiological studies showed that domperidone was associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death (see section 4.8). A higher risk was observed in patients older than 60 years, patients taking daily doses greater than 30 mg, and patients concurrently taking QT-prolonging drugs or CYP3A4 inhibitors.",
          "Domperidone should be used at the lowest effective dose in adults and adolescents 12 years of age and older.",
          "Domperidone is contraindicated in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure due to increased risk of ventricular arrhythmia (see section 4.3.). Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) or bradycardia are known to be conditions increasing the proarrythmic risk.",
          "Treatment with domperidone should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patients should consult their physician.",
          "Patients should be advised to promptly report any cardiac symptoms.",
          "The oral suspension contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. The oral suspension includes propylhydroxybenzoate (E216) and methylhydroxybenzoate (E218) which may cause allergic reactions (possibly delayed).",
        ]),
    Drug(
        id: 'domp5',
        tradeName: 'MOTINORM 5 MG/5ML SUSP. 125 ML',
        genericName: 'DOMPERIDONE 100MG/100ML ORAL SUSP',
        cat: 'GIT',
        contra: [
          " Known hypersensitivity to domperidone or any of the excipients",
          " Prolactin-releasing pituitary tumour (prolactinoma).",
          " when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          " in patients with moderate or severe hepatic impairment",
          " in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          " co-administration with QT-prolonging drugs, at the exception of apomorphine",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Known hypersensitivity to domperidone or any of the excipients",
          "Prolactin-releasing pituitary tumour (prolactinoma).",
          "when stimulation of the gastric motility could be harmful, e.g .,in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.",
          "in patients with moderate or severe hepatic impairment",
          "in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure",
          "co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)",
          "Domperidone has been associated with prolongation of the QT interval on the electrocardiogram. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking domperidone. These reports included patients with confounding risk factors, electrolyte abnormalities and concomitant treatment which may have been contributing factors",
          "Epidemiological studies showed that domperidone was associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death (see section 4.8). A higher risk was observed in patients older than 60 years, patients taking daily doses greater than 30 mg, and patients concurrently taking QT-prolonging drugs or CYP3A4 inhibitors.",
          "Domperidone should be used at the lowest effective dose in adults and adolescents 12 years of age and older.",
          "Domperidone is contraindicated in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure due to increased risk of ventricular arrhythmia (see section 4.3.). Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) or bradycardia are known to be conditions increasing the proarrythmic risk.",
          "Treatment with domperidone should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patients should consult their physician.",
          "Patients should be advised to promptly report any cardiac symptoms.",
          "The oral suspension contains sorbitol (E420). Patients with rare hereditary problems of fructose intolerance should not take this medicine. The oral suspension includes propylhydroxybenzoate (E216) and methylhydroxybenzoate (E218) which may cause allergic reactions (possibly delayed).",
        ]),
    Drug(
        id: 'lact1',
        tradeName: 'DUPHALAC 667GM/L SYRUP 200ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact2',
        tradeName: 'FARCOLAC 667GM/L SYRUP 120 ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact3',
        tradeName: 'LACTOLINE 50% SYRUP 120ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact4',
        tradeName: 'LACTOLINE 50% SYRUP 200ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact5',
        tradeName: 'LACTULAX 67% SYRUP120ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact6',
        tradeName: 'LACTULOSE HEK 65% SYRUP 120ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact7',
        tradeName: 'LACTULOSE HEK 65% SYRUP 300ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact8',
        tradeName: 'LAEVOLAC 67GM/100ML SYRUP 120 ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact9',
        tradeName: 'LAXOLAC 3.35GM/5ML SYRUP 120ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact10',
        tradeName: 'LAXOLAC 3.35GM/5ML SYRUP 300ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact11',
        tradeName: 'SEDALAC 3.35GM/5ML SYRUP 120ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact12',
        tradeName: 'SEDALAC 3.35GM/5ML SYRUP 300ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact13',
        tradeName: 'VILLAPURG 67% SYRUP 120 ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact14',
        tradeName: 'VILLAPURG 67% SYRUP 200 ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'lact15',
        tradeName: 'Golden lax syrup 120 ML',
        genericName: 'LACTULOSE',
        cat: 'GIT',
        contra: [
          "Galactosemia (patients require low-galactose diet)",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Diabetes (preparation contains lactose and galactose)",
          "Monitor for electrolyte imbalance when drug is used for >6 months or in patients predisposed to electrolyte abnormalities",
          "Avoid using other laxatives concomitantly",
          "Inadequate response possible when taken concomitantly with anti-infective",
        ]),
    Drug(
        id: 'docusate1',
        tradeName: 'EGYCUSATE 20 MG/5 ML SYRUP 100ML',
        genericName: 'DOCUSATE SODIUM',
        cat: 'GIT',
        contra: [
          "Hypersensitivity",
          "Intestinal obstruction, symptoms of appendicitis or acute abdominal pain, fecal impaction",
          "Concomitant use of mineral oil",
          "Nausea or vomiting",
          "Use for longer than 7 days when self-medicating",
        ],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Hypersensitivity",
          "Intestinal obstruction, symptoms of appendicitis or acute abdominal pain, fecal impaction",
          "Concomitant use of mineral oil",
          "Nausea or vomiting",
          "Use for longer than 7 days when self-medicating",
          "Electrolyte imbalance may occur with excessive use",
          "Excessive use may result in dependence",
          "Enema is for rectal use only; lubricate prior to insertion; discontinue use and notify health care professional if irritation occurs around the anus/rectal or if resistance is encountered with insertion; injury or damage to the rectum can occur if tube forced",
          "Prior to OTC use, patient should contact healthcare professional if stomach pain, nausea, or vomiting are present, or if a sudden change in bowel habits occurs and persists over 14 days",
          "Patient should discontinue use and notify healthcare professional if bleeding occurs, if bowel movement fails to occur after use, or need to continue use after using for 7 days",
        ]),
    Drug(
        id: 'simeth1',
        tradeName: 'BABY REST 40MG/0.6ML ORAL DROPS 15 ML',
        genericName: 'SIMETHICONE',
        cat: 'GIT',
        contra: ["Hypersensitivity to simethicone"],
        conc: 5 / 24,
        minD: 0,
        maxD: 0,
        freq: 'PO q8h for 7 days',
        doseNote: '',
        prec: [
          "Can cause false-negative gastric guaiac test",
        ]),
  ];

  List<Drug> get drugs {
    return [..._drugs];
  }

  List<Drug> get antipyretics {
    return _drugs.where((element) => element.cat == 'Antipyretic').toList();
  }

  List<Drug> get antibiotics {
    return _drugs.where((element) => element.cat == 'Antibiotics').toList();
  }

  List<Drug> get commomCold {
    return _drugs.where((element) => element.cat == 'Common Cold').toList();
  }

  List<Drug> get git {
    return _drugs.where((element) => element.cat == 'GIT').toList();
  }

  List<Drug> get respiratory {
    return _drugs.where((element) => element.cat == 'Respiratory').toList();
  }
}
